GSA Capital Partners’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,835
| Closed | -$250K | – | 1627 |
|
|
2024
Q4 | $250K | Sell |
7,835
-20,749
| -73% | -$662K | 0.02% | 1311 |
|
|
2024
Q3 | $824K | Buy |
+28,584
| New | +$824K | 0.06% | 592 |
|
|
2022
Q2 | – | Sell |
-17,303
| Closed | -$879K | – | 1377 |
|
|
2022
Q1 | $879K | Buy |
+17,303
| New | +$879K | 0.12% | 230 |
|
|
2021
Q3 | – | Sell |
-17,447
| Closed | -$1.1M | – | 1400 |
|
|
2021
Q2 | $1.1M | Buy |
17,447
+9,100
| +109% | +$575K | 0.12% | 211 |
|
|
2021
Q1 | $358K | Buy |
8,347
+2,132
| +34% | +$91.4K | 0.06% | 538 |
|
|
2020
Q4 | $355K | Sell |
6,215
-9,266
| -60% | -$529K | 0.06% | 647 |
|
|
2020
Q3 | $467K | Buy |
+15,481
| New | +$467K | 0.08% | 434 |
|
|
2020
Q1 | – | Sell |
-10,461
| Closed | -$320K | – | 1041 |
|
|
2019
Q4 | $320K | Buy |
+10,461
| New | +$320K | 0.04% | 974 |
|